Author: Mercy Heimbach
Stopping the storm A Berkeley Heights biopharma company is supporting research into whether two of its drugs might help COVID-19 patients
| NJ Biz

Cyclacel Pharmaceuticals Inc., a Berkeley Heights-based biopharmaceutical company, has entered into an agreement with the University of Edinburgh to study its clinical stage CDK2/9 inhibitors, as potential early treatments for the inflammatory response observed in patients with COVID-19 disease. The partners will assess the suitability of Cyclacel’s medicines for use in safety and experimental studies. […]

Pass the MUST-ARDS: Athersys starts pivotal study for stem cells to treat COVID-19-induced ARDS
| BioWorld

Stem cells haven’t exactly panned out as hoped when it comes to approved therapeutics. There are only a couple that have received a nod from the FDA in very specific indications. But the ongoing COVID-19 pandemic could push stem cells back into the limelight and more firmly establish them as therapeutically relevant. There are at least a few […]

Trovagene Rebrands as Cardiff Oncology, Promotes Longtime Exec to CEO
| Xconomy

Trovagene (NASDAQ: TROV), which started out as a diagnostics company, has renamed itself Cardiff Oncology to better reflect its focus on the cancer drug it is advancing in three clinical trials. In 2017 the San Diego area-based biotech made the first step in its transformation into a drug development-focused organization, licensing rights to an investigational cancer drug from […]